Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.52 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11187322 | 0.93 | ESR1 (0.55) | ESR1ESR2CNR1BCHEMCHR1 | |
| SCHEMBL11192824 | 0.92 | ESR1 (0.48) | ESR1ESR2CNR1BCHEMCHR1 | |
| SCHEMBL11178289 | 0.92 | ESR1 (0.50) | ESR1ESR2BCHEMCHR1CACNA1B | |
| SCHEMBL4653145 | 0.90 | MCHR1 (0.54) | ESR1ESR2CNR1BCHECNR2 | |
| SCHEMBL3886456 | 0.90 | ESR1 (0.54) | ESR1ESR2CNR1BCHECNR2 | |
| SCHEMBL4651133 | 0.89 | MCHR1 (0.58) | ESR1ESR2CNR1BCHECNR2 | |
| SCHEMBL7942835 | 0.87 | ALDH1A1 (0.46) | ESR1ESR2CNR1CNR2SMN1; SMN2 | |
| SCHEMBL27604706 | 0.86 | LTA4H (0.47) | ESR1ESR2CNR1BCHECNR2 | |
| SCHEMBL7946063 | 0.84 | ESR1 (0.49) | ESR1ESR2SMN1; SMN2ALDH1A1GAA | |
| Trioxifene SCHEMBL4651963 | 0.83 | ESR1 (0.69) | ESR1ESR2MCHR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127440-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide Y activity | BAYLOR COLLEGE OF MEDICINE | 2004-07-01 | — | — | US | claimed |
| US-20040053864-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide y activity | BAYLOR COLLEGE OF MEDICINE | 2004-03-18 | — | — | US | claimed |
| WO-2001053477-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF BONE FORMATION VIA MODULATION OF NEUROPEPTIDE Y ACTIVITY | BAYLOR COLLEGE OF MEDICINE (US) | 2001-07-26 | — | — | WO | claimed |
| EP-0735821-A4 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | LILLY CO ELI (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0736007-A4 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0736007-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0735821-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0716854-A2 | Compositions for inhibiting neuropeptide y receptors | ELI LILLY AND COMPANY (US) | 1996-06-19 | — | — | EP | claimed |
| US-5514675-A | ADMINISTERING TO TREAT ASTHMA, RHINITIS, AND PAIN; ANTISHOCK AND HYPOTENSIVE AGENTS | ELI LILLY AND COMPANY (US) | 1996-05-07 | — | — | US | claimed |
| WO-1996012489-A1 | BICYCLIC NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012488-A1 | BICYCLIC BRADYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0709090-A2 | Compositions for treating resistant tumors | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1996011677-A1 | METHODS FOR TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-04-25 | — | — | WO | claimed |
| EP-0707852-A2 | Bicyclic bradykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | claimed |
| US-5491140-A | ADMINISTERING TO A MAMMAL SUFFERING FROM NERVOUS SYSTEM DISORDERS, RESPIRATORY SYSTEM DISORDERS, UROGENITAL DISORDERS ARTHRITIS, RHEUMATOID, OSTEOPROSIS, PERSISTENT PAIN, MIGRAIN OR POST-OPERATIVE PAIN | ELI LILLY AND COMPANY (US) | 1996-02-13 | — | — | US | claimed |
| WO-1995017095-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | claimed |
| WO-1995017382-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | claimed |
| EP-2002827-A2 | Methods and compositions for control of bone formation via modulation of sympathetic tone | THE BAYLOR COLLEGE OF MEDICINE (US) | 2008-12-17 | — | — | EP | disclosed |
| US-4237162-A | MITICIDES, LARVACIDES, INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-02 | — | — | US | disclosed |
| US-4230862-A | 3-PHENYL-4-AROYL-1,2-DIHYDRONAPHTHALENES AND 1-ARYOYL-2-PHENYLNAPHTHALENES | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |